Literature DB >> 1151617

Elimination rate of N-acetylprocainamide after a single intravenous dose of procainamide hydrochloride in man.

C Graffner.   

Abstract

Equations were derived which made it possible to determine the elimination rate of N-acetylprocainamide from urinary data after intravenous administration of procainamide hydrochloride. A single dose of 500 mg of the drug was infused intravenously in four healthy subjects. On the basis of theose equations, the formation rate of the metabolite could be calculated presuming that all rate processes were occurring by first-order processes. However, close examination of the excretion rate data appears to support the contention that the formation or excretion of N-acetylprocainamide may be occurring by a saturable process

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1151617     DOI: 10.1007/bf01066016

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  5 in total

1.  The physiological disposition and cardiac effects of procaine amide.

Authors:  L C MARK; H J KAYDEN; J M STEELE; J R COOPER; I BERLIN; E A ROVENSTINE; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1951-05       Impact factor: 4.030

2.  Plasma levels of procaine amide after administration of conventional and sustained-release tablets.

Authors:  E Karlsson
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

3.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

4.  Metabolism of procainamide in rhesus monkey and man.

Authors:  J Dreyfuss; J T Bigger; A I Cohen; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

5.  Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets.

Authors:  C Graffner; G Johnsson; J Sjögren
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

  5 in total
  6 in total

1.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

2.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

3.  Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation.

Authors:  R A Ahmad; H J Rogers; M Vandenburg; P Wright
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

4.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

5.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

Review 6.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.